stoxline Quote Chart Rank Option Currency Glossary
Cybin Inc. (CYBN)
0.415  -0.015 (-3.49%)    12-07 16:00
Open: 0.4208
High: 0.4289
Volume: 2,855,251
Pre. Close: 0.43
Low: 0.4
Market Cap: 168(M)
Technical analysis
2023-12-07 4:19:58 PM
Short term     
Mid term     
Targets 6-month :  0.62 1-year :  0.72
Resists First :  0.53 Second :  0.62
Pivot price 0.45
Supports First :  0.39 Second :  0.33
MAs MA(5) :  0.43 MA(20) :  0.45
MA(100) :  0.44 MA(250) :  0.39
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  11.9 D(3) :  16.5
RSI RSI(14): 36.8
52-week High :  0.73 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed below the lower bollinger band by 2.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.43 - 0.43 0.43 - 0.44
Low: 0.4 - 0.41 0.41 - 0.41
Close: 0.42 - 0.43 0.43 - 0.44
Company Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Headline News

Wed, 06 Dec 2023
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program - Business Wire

Tue, 05 Dec 2023
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual ... - Business Wire

Thu, 30 Nov 2023
Cybin reports positive Phase 2 data for depression drug, files SEC Form D - Seeking Alpha

Thu, 30 Nov 2023
Cybin Inc (CYBN) Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder -

Wed, 29 Nov 2023
Should Biotechnology Stock Cybin Inc (CYBN) Be in Your Portfolio Wednesday? - InvestorsObserver

Wed, 15 Nov 2023
Cybin Expects Phase 3 Data on CYB003 in 2024 - Green Market Report

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android